Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Delgocitinib ointment 30 mg/g was more effective than vehicle control for improving skin clearance and disease severity in a study of patients with chronic hand eczema. Findings from this study were published in the British Journal of Dermatology.
Patients with chronic hand eczema were randomly assigned to either delgocitinib ointment 30 mg/g (n=60) or vehicle ointment control (n=31), both of which were applied twice a day on the hands for an 8-week treatment period. At 8 weeks, the researchers compared the groups in terms of the proportion of patients who achieved treatment success, or “clear”/”almost clear” skin with a ≥2-point improvement in the Physician’s Global Assessment of disease severity. The investigators also looked at changes in the Hand Eczema Severity Index score, as well as the proportion of patients who achieved treatment success on the Patient’s Global Assessment of disease severity at 8-week follow-up.
Application of delgocitinib ointment was associated with a significantly higher proportion of patients achieving treatment success (45.7% vs 14.9%, respectively; odds ratio, 4.89; 95% CI, 1.49-16.09; P =.009). At week 8, a significantly lower adjusted mean Hand Eczema Severity Index score was observed in patients treated with delgocitinib vs vehicle control (13.0 vs 25.8, respectively; adjusted mean difference, −12.88; 95% CI, −21.47 to −4.30; P =.003). Although a greater number of patients who were randomly assigned to delgocitinib achieved treatment success based on Patient’s Global Assessment of disease severity, the difference was not statistically significant. In addition, no difference was observed between delgocitinib and vehicle, in terms of the incidence of adverse events.
Limitations of the study include its small sample size as well as relatively short duration of follow-up.
“As a plateau in treatment success with delgocitinib was not observed after 8 weeks,” the researchers wrote, “we could speculate that a longer treatment period may lead to increased efficacy.”
Disclosure: Several study authors declared affiliations with the pharmaceutical industry. This clinical trial was supported by LEO Pharma. Please see the original reference for a full list of authors’ disclosures.
Reference
Worm M, Bauer A, Elsner P, et al. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomised, double-blind, vehicle-controlled Phase 2a study [published online August 29, 2019]. Br J Dermatol. doi:10.1111/bjd.18469
